Less than half of patients diagnosed with TD residing in LTC settings received the standard of care treatment recommended by the American Psychiatric Association – a vesicular monoamine transporter 2 ...

A copy of the Early Warning Report filed by CEO will be available under the Company’s profile on SEDAR at www.sedarplus.ca or may be obtained from José Roldan, Interim CFO, at jroldan@rammpharma.com.

The Company has experienced dramatic user growth over the past two years as can be seen by the consistent revenue growth over the past eight quarters. Net loss and comprehensive loss have improved ...

NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (“ 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...

Mont-Saint-Guibert (Belgique), le 30 mai 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext ...

Louvain-la-Neuve, Belgium, May 30th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA ...

The Company continues to work diligently to complete its Form 10-Q for the period ended March 31, 2025, after which the Company anticipates maintaining compliance with its SEC reporting obligations.

Mr. Puccetti has been appointed as Chair of the Reconstituted Board. The Audit Committee now consists of Mr. Spear (Committee Chair), Mr. Kosciessa and Mr. Puccetti. The Human Resources, Nominating ...

Mr. Abernethy began his career with KPMG LLP and became a certified public accountant (currently inactive). Mr. Abernethy holds a B.S. in Accounting and Business Administration from Grace College and ...

Russell Bradley as President and General Manager of Plus Therapeutics’ wholly owned subsidiary, CNSide Diagnostics, LLC (“CNSide Diagnostics”) - Mr. Bradley provides leadership to CNSide Diagnostics ...

Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to ...